RNA-binding protein FUS, Proteintech, 60160-1-Ig

Our team has carried out an in-depth review of the published scientific literature to identify papers and reports using antibodies directed against the human RNA-binding protein Fused-in-Sarcoma, followed by extraction and evaluation of the available data to assess performance according to the pAbmAbs rating criteria.

YCharOS is conducting a large head-to-head study comparing 18 commercially available research antibodies against the human RNA-binding protein Fused-in-Sarcoma encoded by FUS.

The collection of antibodies was tested using HeLa WT and FUS KO cells in the applications WB (WT and KO cell lysates, 30 µg protein), IP (WT cell lysate), IF (WT and KO cells), and flow cytometry (WT and KO cells). Some antibodies were evaluated across multiple applications, whereas others were tested exclusively by flow cytometry, all according to YCharOS standard protocols (see reference).

In WB (1:10000 Ab dilution) 60160-1-Ig detected a band at appr. 70 kDa in WT cell lysate with no corresponding bond observed in KO cell lysate. Very strong background band was observed for both genotypes. A band was also detected following IP (1 µg Ab used). This band was not more intense than the corresponding band in input extract (10% of starting material) and a band was also detected in immunodepleted extract (10% of total unbound fraction), showing that the antibody does not completely deplete the antigen from the cell lysate. In IF (1:2000 Ab dilution), an intense staining of WT cells was observed compared to KO cell staining, which showed some background staining.

We highly encourage other scientists to share their observations.